Therapeutic use of anti-CTLA-4 antibodies

被引：91

作者：

Blank, Christian U. ^{[1
,2
]}

Enk, Alexander ^{[3
]}

机构：

[1] Netherlands Canc Inst, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands

[2] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands

[3] Heidelberg Univ, Dept Dermatol, D-69115 Heidelberg, Germany

来源：

INTERNATIONAL IMMUNOLOGY | 2015年 / 27卷 / 01期

关键词：

CTLA-4; immune checkpoint blockade; ipilimumab; PD-1; PD-L1; T cell; tremelimumab; REGULATORY T-CELLS; PRETREATED ADVANCED MELANOMA; ISOLATED LIMB PERFUSION; STAGE-IV MELANOMA; METASTATIC MELANOMA; DENDRITIC CELLS; CTLA-4; BLOCKADE; CUTTING EDGE; PHASE-II; TRYPTOPHAN CATABOLISM;

D O I：

10.1093/intimm/dxu076

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Targeting CTLA-4 represents a new type of immunotherapeutic approach, namely immune checkpoint inhibition. Blockade of CTLA-4 by ipilimumab was the first strategy to achieve a significant clinical benefit for late-stage melanoma patients in two phase 3 trials. These results fueled the notion of immunotherapy being the breakthrough strategy for oncology in 2013. Subsequently, many trials have been set up to test various immune checkpoint modulators in malignancies, not only in melanoma. In this review, recent new ideas about the mechanism of action of CTLA-4 blockade, its current and future therapeutic use, and the intensive search for biomarkers for response will be discussed. Immune checkpoint blockade, targeting CTLA-4 and/or PD-1/PD-L1, is currently the most promising systemic therapeutic approach to achieve long-lasting responses or even cure in many types of cancer, not just in patients with melanoma.

引用

页码：3 / 10

页数：8

共 87 条

[1] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].

Ahmadzadeh, Mojgan ;

Johnson, Laura A. ;

Heemskerk, Bianca ;

Wunderlich, John R. ;

Dudley, Mark E. ;

White, Donald E. ;

Rosenberg, Steven A. .

BLOOD, 2009, 114 (08) :1537-1544

[2] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[3] Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon [J].

Ascierto, Paolo A. ;

Chiarion-Sileni, Vanna ;

Muggiano, Antonio ;

Mandala, Mario ;

Pimpinelli, Nicola ;

Del Vecchio, Michele ;

Rinaldi, Gaetana ;

Simeone, Ester ;

Queirolo, Paola .

JOURNAL OF CHEMOTHERAPY, 2014, 26 (04) :193-201

[4] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 [J].

Attia, P ;

Phan, GQ ;

Maker, AV ;

Robinson, MR ;

Quezado, MM ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Kammula, US ;

Royal, RE ;

Restifo, NP ;

Haworth, LR ;

Levy, C ;

Mavroukakis, SA ;

Nichol, G ;

Yellin, MJ ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6043-6053

[5] Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade [J].

Breunis, Willemijn B. ;

Tarazona-Santos, Eduardo ;

Chen, Renee ;

Kiley, Maureen ;

Rosenberg, Steven A. ;

Chanock, Stephen J. .

JOURNAL OF IMMUNOTHERAPY, 2008, 31 (06) :586-590

[6] Properties of mouse and human IgG receptors and their contribution to disease models [J].

Bruhns, Pierre .

BLOOD, 2012, 119 (24) :5640-5649

[7] A NEW MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY - CTLA-4 [J].

BRUNET, JF ;

DENIZOT, F ;

LUCIANI, MF ;

ROUXDOSSETO, M ;

SUZAN, M ;

MATTEI, MG ;

GOLSTEIN, P .

NATURE, 1987, 328 (6127) :267-270

[8] OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy [J].

Bulliard, Yannick ;

Jolicoeur, Rose ;

Zhang, Jimin ;

Dranoff, Glenn ;

Wilson, Nicholas S. ;

Brogdon, Jennifer L. .

IMMUNOLOGY AND CELL BIOLOGY, 2014, 92 (06) :475-480

[9] Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies [J].

Bulliard, Yannick ;

Jolicoeur, Rose ;

Windman, Maurice ;

Rue, Sarah M. ;

Ettenberg, Seth ;

Knee, Deborah A. ;

Wilson, Nicholas S. ;

Dranoff, Glenn ;

Brogdon, Jennifer L. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2013, 210 (09) :1685-1693

[10] Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma [J].

Camacho, Luis H. ;

Antonia, Scott ;

Sosman, Jeffrey ;

Kirkwood, John M. ;

Gajewski, Thomas F. ;

Redman, Bruce ;

Pavlov, Dmitri ;

Bulanhagui, Cecile ;

Bozon, Viviana A. ;

Gomez-Navarro, Jesus ;

Ribas, Antoni .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1075-1081

← 1 2 3 4 5 6 7 8 9 →